We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How the MHRA assesses marketing authorisation applications (MAA) for medicines referred under Article 29.
A set of principles for understanding the impact of new variants on antiviral drugs and monoclonal antibodies
Extra information for the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) Integrated Scientific Advice (ISA) service.
Supplementary information for international regulators on packaging changes and the export of UK medicines.
MHRA scientific and regulatory advice for COVID-19 vaccine developers
If pharmacies wish to ‘pack down’ larger packs of a medicinal product, they need to follow these instructions
The UK government has introduced the Northern Ireland MHRA Authorised Route (NIMAR). This new route for supply became operational 1 January 2022.
A series of webinars providing guidance on the Windsor Framework agreement and the supply of medicines in Northern Ireland.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).